Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Cognizant Technology Solutions Corp (CTSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Cognizant Technology Solutions Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Cognizant Technology Solutions Corp trades at $42.9 (market cap $20.13B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Cognizant Technology Solutions Corp pays a 3.1% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CTSH | |
|---|---|---|
Market Cap | $39.89B | $20.13B |
Sector | Health | Technology |
52-Week High | $491.22 | $86.70 |
52-Week Low | $278.09 | $38.73 |
Enterprise Value | $38.15B | $19.71B |
Dividend Yield | — | 3.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
CTSH trades at $42.57, down 1.91% on the day, with a bearish technical signal despite strong fundamentals including a P/E of 9.23 and consistent earnings beats. Recent news highlights AI partnerships with Google Cloud and OpenAI, while cash flow improved in 2025 to $403M. The stock faces near-term pressure from weak demand and competition, but analyst consensus targets $64.33.
The outlook balances attractive valuation against sector rotation headwinds. Opportunities include AI-driven growth and shareholder returns via dividends, but risks involve margin pressure and technical resistance near $44. Wall Street sentiment is mixed with 43% buy ratings, suggesting cautious optimism for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →
